The U.S. diagnostics industry is being strangled, and other life science inventions are being hobbled by, ill-conceived and contradictory patent policies. The USPTO director has signaled he wants to help, but only Congress has the...

LabCorp will acquire fellow diagnostics company Sequenom for $2.40 per share in cash, or about $371 million including Sequenom’s net debt. The price is a 182% premium to Sequenom’s close of $0.85 on July 26,...

Diagnostics company Laboratory Corp. of America Holdings (NYSE:LH) is acquiring Sequenom Inc. (NASDAQ:SQNM) for $2.40 per share, or about $371 million including Sequenom's net debt. The price is a 182% premium to Sequenom's close of...

The U.S. Supreme Court declined to review a lower court decision invalidating U.S. Patent No. 6,258,540 covering prenatal diagnosis with nucleic acid analysis used in Sequenom’s MaterniT21 Plus laboratory-developed test. Sequenom had asked SCOTUS to...

The U.S. Court of Appeals for the Federal Circuit found that a patent covering a process for preserving hepatocytes by multiple freeze-thaw cycles was not directed to a patent-ineligible law of nature, vacating a lower...

In a blow to the diagnostics industry, the U.S. Supreme Court declined to review a lower court's decision that had invalidated a patent owned by Sequenom Inc. (NASDAQ:SQNM) covering a prenatal diagnostic test. The company...

Cancer company ImmunoGen Inc. (NASDAQ:IMGN) hired Mark Enyedy as president, CEO and a director, effective May 16. Enyedy was EVP and head of corporate development at Shire plc (LSE:SHP; NASDAQ:SHPG). He replaces Daniel Junius, who...

Restructuring watch Date Company Staff cuts Cash Yrs cash pre-cut Cash date 12-mo op loss ended 12/31 1/7/16 Sequenom Inc. (NASDAQ:SQNM) 20% to 390 $76.2 9.65 12/31/15 $7.9 Sequenom restructured to focus on women's health...

Anthem Blue Cross and Blue Shield of Connecticut, Maine and New Hampshire will cover Sequenom’s noninvasive prenatal tests for high- and average-risk pregnancies. The company’s products include MaterniT21 Plus LDT, which detects trisomies along with...

Sequenom said it will reduce headcount by about 110 (20%) to about 390 and restructure to focus on women’s health, including R&D programs for tests serving obstetricians, gynecologists and maternal fetal medicine specialists, and expanding...